Alembic Pharmaceuticals passes ANVISA GMP inspection at Karakhadi facility

Kinjal — Fri, 15 May 2026 14:58:50 +0000

Alembic Pharmaceuticals has successfully completed the Good Manufacturing Practice (GMP) inspection conducted by the Brazilian Health Regulatory Agency (ANVISA) at its API-III facility in Karakhadi. The inspection, which took place from 11th May to 15th May 2026, concluded without any observations.

The API-III facility at Karakhadi was evaluated for multiple active pharmaceutical ingredients (APIs) during the inspection. The successful completion of this inspection signifies that the facility meets the stringent quality and manufacturing standards set by ANVISA, which is essential for exporting pharmaceutical products to Brazil.

The inspection’s positive outcome is a significant milestone for Alembic Pharmaceuticals, as it reinforces the company’s commitment to maintaining high-quality manufacturing practices and regulatory compliance. This achievement is expected to bolster Alembic’s position in the Brazilian market and enhance its reputation as a reliable supplier of pharmaceutical products.

Alembic Pharmaceuticals, headquartered in Vadodara, has been consistently expanding its global footprint by adhering to international regulatory standards. The company continues to focus on innovation and quality to meet the growing demands of the pharmaceutical industry.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

ANVISA | Business Upturn

Alembic Pharmaceuticals passes ANVISA GMP inspection at Karakhadi facility